Regeneron Pharmaceuticals and Sanofi said their rheumatoid arthritis drug Kevzara failed to meet the main goals of a U.S. study testing the medicine in the most critically ill COVID-19 patients.
A federal appeals court upheld two patents for Amgen’s multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis’ effort to void the patents.
Eli Lilly will assess the company’s JAK1/JAK2 inhibitor Olumiant (baricitinib) as a potential treatment for COVID-19 in a Phase III study.
Exclusive: Lilly COVID-19 treatment could be authorized for use as soon as September – chief scientist (Reuters) – Eli Lilly and Co could have a drug specifically designed to treat COVID-19 authorized for use as early as September if all goes well with either of two antibody therapies it is testing, its chief scientist told […]
Roche and Gilead Sciences launched a Phase III clinical trial in severe COVID-19 pneumonia, testing Roche’s Actemra/RoActemra with Gilead’s remdesivir.
Novartis won the go-ahead from the U.S. Food and Drug Administration to conduct a randomized trial of the malaria drug hydroxychloroquine against COVID-19 disease to see if the medicine helps patients.
Roche Holding AG Chief Executive Officer Severin Schwan said in an interview with CNBC it could take at least a couple of weeks, if not months, for the United States to implement broad testing for coronavirus.
Gilead Sciences and Eisai entered into an agreement for the distribution and co-promotion of the investigational, oral, selective JAK1 inhibitor filgotinib in Japan, pending regulatory approval for the treatment of rheumatoid arthritis (RA).
Gilead Sciences Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the investigational, oral, selective JAK1 inhibitor filgotinib for the treatment of adults who are living with moderate-to-severe rheumatoid arthritis.
China’s Bio-Thera Solutions Ltd. won a regulatory approval for the company’s version of AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market.